| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/11/2010 | US20100062024 Biologically Active Hemagglutinin From Type A Clostridium Botulinum and Methods of Use |
| 03/11/2010 | US20100062023 Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi |
| 03/11/2010 | US20100062022 Immunogenic proteins of burkholderia pseudomallei and uses thereof |
| 03/11/2010 | US20100062021 Vaccination for lawsonia intracellularis |
| 03/11/2010 | US20100062020 Method of Treating a Malignancy in a Subject Via Direct Picornaviral-Mediated Oncolysis |
| 03/11/2010 | US20100062019 New vaccine formulations |
| 03/11/2010 | US20100062018 Mycoplasma hyopneumoniae bacterin vaccine |
| 03/11/2010 | US20100062017 Pasteurella multocida vaccine |
| 03/11/2010 | US20100062016 Microorganisms for therapy |
| 03/11/2010 | US20100062015 Fusion protein vaccine |
| 03/11/2010 | US20100062014 H3 equine influenza a virus |
| 03/11/2010 | US20100062013 Cancer antigen peptides derived from wt1 |
| 03/11/2010 | US20100062012 Negative Genetic Regulation of Cancer Cell Renewal in Synergy with Notch- or Numb-Specific Immunotherapy |
| 03/11/2010 | US20100062011 Peptide Vaccine for Inducing the Production of Anti-Amyloid ß-Peptide Antibody |
| 03/11/2010 | US20100062010 Novel peptide compound |
| 03/11/2010 | US20100062009 for cancer, immune, infectious and ischemic diseases; inhibiting tumor growth; allergy |
| 03/11/2010 | US20100062008 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 03/11/2010 | US20100062007 Multi-modal cancer therapy using viral hitch-hiking |
| 03/11/2010 | US20100062006 Treatment of stomach cancer with steroid compounds and precipitation |
| 03/11/2010 | US20100062005 Methods and Compounds for Lymphoma Cell Detection and Isolation |
| 03/11/2010 | US20100062004 Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| 03/11/2010 | US20100062003 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 03/11/2010 | US20100062002 Brain Endothelial Cell Expression Patterns |
| 03/11/2010 | US20100062001 Antibodies for selective apoptosis of cells |
| 03/11/2010 | US20100062000 Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations |
| 03/11/2010 | US20100061999 Antihuman tnf-alpha antibody activity lowering inhibitor |
| 03/11/2010 | US20100061998 Il-1beta binding antibodies and fragments thereof |
| 03/11/2010 | US20100061997 Transgenic Non-Human Animals Expressing A Truncated Activin Type II Receptor |
| 03/11/2010 | US20100061996 Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator |
| 03/11/2010 | US20100061995 Immunotherapy To Treat Or Prevent Viral Infection |
| 03/11/2010 | US20100061994 Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| 03/11/2010 | US20100061993 Antibodies |
| 03/11/2010 | US20100061992 Therapeutic uses of tim-3 modulators |
| 03/11/2010 | US20100061991 Identification of therapeutic agents for HIV infection |
| 03/11/2010 | US20100061990 Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
| 03/11/2010 | US20100061989 Method of treatment and prophylaxis |
| 03/11/2010 | US20100061988 Monoclonal antibodies |
| 03/11/2010 | US20100061987 High Affinity Antibodies Against HMGB1 and Methods Of Use Thereof |
| 03/11/2010 | US20100061986 Chronic Rejection Inhibitor |
| 03/11/2010 | US20100061985 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 03/11/2010 | US20100061984 Compositions and methods for modulation of suppressor t cell activation |
| 03/11/2010 | US20100061983 Method of inhibiting leukocytes with human cxc chemokine receptor 3 antibody |
| 03/11/2010 | US20100061982 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 03/11/2010 | US20100061981 p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING |
| 03/11/2010 | US20100061980 Assays to predict and monitor antibody mediated rejection of transplanted allografts |
| 03/11/2010 | US20100061979 Modified soluble fgf receptor fc fusions wsith improved biological activity |
| 03/11/2010 | US20100061978 Methods for detecting and treating cancer |
| 03/11/2010 | US20100061977 Methods and compositions for treating and diagnosing diseases |
| 03/11/2010 | US20100061976 Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject |
| 03/11/2010 | US20100061975 Uses for 4,17B-dihydroxyandrost-4-ene-3-one |
| 03/11/2010 | US20100061974 Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
| 03/11/2010 | US20100061973 Graded Expression of Snail as Marker of Cancer Development and DNA Damage-Based Diseases |
| 03/11/2010 | US20100061935 Methods of using sustained release aminopyridine compositions |
| 03/11/2010 | US20100061934 Methods for diagnosis or treatment of amyloidosis by targeting hyper-sulfated proteoglycans present in amyloid |
| 03/11/2010 | US20100061933 Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| 03/11/2010 | DE102008045815A1 Combination of an antibody and a bacterium, which expresses Fc-receptors or proteins, which bind the light chain of an antibody, useful for the treatment of tumors and their precursors, preferably colorectal carcinoma |
| 03/11/2010 | CA2738034A1 Materials and methods for inhibiting cancer cell invasion related to fgfr4 |
| 03/11/2010 | CA2736799A1 Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
| 03/11/2010 | CA2736187A1 Novel compositions and adjuvants |
| 03/11/2010 | CA2736151A1 Outer membrane vesicle prime - protein boost vaccine |
| 03/11/2010 | CA2736134A1 Lps based vaccines |
| 03/11/2010 | CA2736029A1 Anti-lipid antibodies |
| 03/11/2010 | CA2735940A1 Methods for treating or preventing il-1.beta. related diseases |
| 03/11/2010 | CA2735939A1 Methods for improvement of beta cell function |
| 03/11/2010 | CA2735910A1 Vaccine comprising protein nmbo964 from meisseria meningitidis |
| 03/11/2010 | CA2735860A1 Synthetic methods and derivatives of triphosphate oligonucleotides |
| 03/11/2010 | CA2735823A1 Use of a truncated eif-5a1 polynucleotide to induce apoptosis in cancer cells |
| 03/11/2010 | CA2735193A1 T-cell receptor antibodies and methods of use thereof |
| 03/11/2010 | CA2735175A1 Antimicrobial protein compositions and production therefor from marine bacteria |
| 03/11/2010 | CA2734905A1 Multispecific antibodies |
| 03/11/2010 | CA2733943A1 Peptides presenting an epitope of an a domain of factor h binding protein and methods of use |
| 03/11/2010 | CA2732338A1 Identification of a conserved inner core oligosaccharide region of moraxella catarrhalis lipopolysaccharide as a vaccine antigen |
| 03/11/2010 | CA2731444A1 Human papillomavirus / li-key hybrids and methods of use |
| 03/11/2010 | CA2730328A1 Immunogenic escherichia coli heat stable enterotoxin |
| 03/10/2010 | EP2161338A1 Isolated mammalian monocyte cell genes; related reagents |
| 03/10/2010 | EP2161286A1 Antibodies |
| 03/10/2010 | EP2161285A1 Monoclonal antibodies for neutralizing anthrax toxin |
| 03/10/2010 | EP2161283A1 Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin |
| 03/10/2010 | EP2161280A2 Genes involved in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications |
| 03/10/2010 | EP2161279A1 Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
| 03/10/2010 | EP2161035A1 Bordetella parapertussis-containing whole-cell vaccine composition |
| 03/10/2010 | EP2160608A1 Diagnostic composition and method for the detection of a trichinella infection |
| 03/10/2010 | EP2160601A1 Method for predicting the response of a patient to treatment with an anti-tnf alpha antibody |
| 03/10/2010 | EP2160466A1 Treatment and prevention of influenza |
| 03/10/2010 | EP2160411A1 Anti-vpac1 antibodies and their uses |
| 03/10/2010 | EP2160409A1 Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors |
| 03/10/2010 | EP2160407A1 Neutralizing antibodies |
| 03/10/2010 | EP2160406A1 Antibodies useful for therapy and diagnosis of cancer |
| 03/10/2010 | EP2160200A1 Antibody-light fusion products for cancer therapeutics |
| 03/10/2010 | EP2160199A2 Class a oligonucleotides with immunostimulatory potency |
| 03/10/2010 | EP2160198A2 Influenza vaccines |
| 03/10/2010 | EP2046378B1 Use of bacterial polysaccharides for biofilm inhibition |
| 03/10/2010 | EP1902320B1 Pretreatment of a biological sample from an autoimmune disease subject |
| 03/10/2010 | EP1641474B1 Therapeutical composition containing dentritic cells and use thereof |
| 03/10/2010 | EP1544293B1 Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same |
| 03/10/2010 | EP1274833B1 A method to prevent graft rejection using tgf-beta to induce t suppressor cells |
| 03/10/2010 | EP0932678B2 A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 03/10/2010 | EP0830146B1 Methods of inducing immune tolerance using immunotoxins |
| 03/10/2010 | CN101668541A Modulation of complement system activation for treatment of bleeding-related inflammation |
| 03/10/2010 | CN101668540A Stable antibody formulations |